Global equities corrected by 2.5% in November led by uncertainty over the impact of new COVID-19 variant
Omicron. Supply-chain pressures are easing and likely to allow equities to continue to deliver strong
revenue growth and record margins. Even for the cohort that faces meaningful disruptions, we expect
these issues largely to abate by 2HFY22, resulting in delayed revenues rather than demand destruction.
The global expansion is in the midst of its first resiliency test, but we remain positive on growth. Looking
ahead, we continue to see market upside, though more moderate, on better-than-expected earnings
growth with supply shocks easing, China/EM backdrop improving and normalizing consumer spending
habits (e.g. spending broadening to services).
Brent and Commodities:
Oil prices suffered a dip after two months of price rally, shedding 16.9% to
near $70/barrel in November as an emerging, heavily mutated COVID variant in South Africa/Botswana
sparked fears that renewed lockdowns and travel bans could hurt global demand. Going forward, the
trend would largely depends on whether the initial fears around Omicron are realized. China retail steel
stocks in warehouses fell to over 9 months low despite severe production cuts. HRC, Billet and Rebar
prices fell by 5%, 2% and 2% respectively, following sharp fall in domestic met coke prices (down 24%
MoM). Export HRC prices also fell 7.1% MoM.